美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

基因編輯

415.85

+8.212.01%

漲家數：5

跌家數：- -

平家數：- -

市盈率：- -

高：427.38

開：410.66

低：410.66

收：407.55

成交量：1,048.05萬

成交額：1.15億

市值：89.29億

流通市值：82.89億

資料載入中...

總覽新聞資訊

BUZZ-基因編輯藥物有望治療罕見肺病和肝病，Beam Therapeutics公司股價上漲

Beam Therapeutics股價盤前飆升14%，基因編輯藥物在罕見肺肝疾病試驗中展現積極成果

Beam Therapeutics公司：60毫克劑量被確定為最佳生物劑量，單劑量隊列展現優異安全性與療效

Beam Therapeutics公布BEAM-302治療α-1抗胰蛋白酶缺乏症1/2期試驗最新積極數據支持推進關鍵性開發階段

Beam Therapeutics：經BEAM-302 60毫克治療後，校正型M-AAT佔總AAT的94%，同時突變型Z-AAT降低84%

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK4556/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK4556","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","market":"US","secType":"PLATE","nameCN":"基因編輯","latestPrice":415.75815,"timestamp":1774455540007,"preClose":407.54913,"halted":0,"volume":10481763,"delay":0,"changeRate":0.020142,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":8.209015,"latestTime":"03-25 12:19:00 EDT","open":410.65607,"high":427.38245,"low":410.65607,"amount":114757211.107688,"amplitude":0.041041,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1774468800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":2.304631,"peRate":-6.631376,"turnoverRate":0.014048,"increases":5,"decrements":0,"flats":0,"marketCap":8928901616,"floatMarketCap":8288805848},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","high":427.38245,"amplitude":0.041041,"preClose":407.54913,"low":410.65607,"pbRate":"2.304631","latestPrice":415.8527,"volume":10480488,"delay":0,"open":410.65607,"prevYearClose":431.70972,"prevWeekClose":410.1447,"prevMonthClose":496.6623,"prevQuarterClose":431.7097,"fiveDayClose":422.4592,"twentyDayClose":478.3519,"sixtyDayClose":447.8402,"secType":"PLATE","market":"US","turnoverRate":0.014048,"peRate":-6.631376,"marketCap":8928901616,"floatMarketCap":8288805848,"timestamp":1774455536537,"nameCN":"基因編輯"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4556\",,,,undefined,":{"bkCode":"BK4556","up":5,"down":0,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4556\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622798020","title":"BUZZ-基因編輯藥物有望治療罕見肺病和肝病，Beam Therapeutics公司股價上漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2622798020","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622798020?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 19:28","pubTimestamp":1774438089,"startTime":"0","endTime":"0","summary":"BUZZ-基因编辑药物有望治疗罕见肺病和肝病，Beam Therapeutics公司股价上涨3月25日 - ** 生物技术公司Beam Therapeutics BEAM.O股价盘前上涨12%至27.01美元** 该公司称其实验性基因编辑药物BEAM-302在一项针对α-1抗胰蛋白酶缺乏症的早期研究中取得了令人鼓舞的结果，α-1抗胰蛋白酶缺乏症是一种可损害肺部和肝脏的罕见遗传性疾病。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37684715aaf54a73b9fe52ee56a263cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL4T40D11C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861558580.USD","BK4535","BK4588","BK4139","BK4556","BEAM","LU1861559042.SGD","BK4611","BK4505","BK4585"],"gpt_icon":0},{"id":"1116095845","title":"Beam Therapeutics股價盤前飆升14%，基因編輯藥物在罕見肺肝疾病試驗中展現積極成果","url":"https://stock-news.laohu8.com/highlight/detail?id=1116095845","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116095845?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 19:19","pubTimestamp":1774437552,"startTime":"0","endTime":"0","summary":"Beam Therapeutics, Inc. (BEAM) 股价在盘前交易中大幅上涨14%，此前该公司宣布其研发的基因编辑药物在一项针对罕见肺肝疾病的临床试验中取得了令人鼓舞的结果。\n这一积极进展显著提振了投资者信心，推动公司股价在开盘前出现强劲上扬。试验数据的披露为Beam Therapeutics在基因治疗领域的技术实力提供了有力证明，同时也为相关罕见疾病患者带来了新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","BK4585","BEAM","LU1861558580.USD","BK4588","BK4535","LU1861559042.SGD","BK4611","BK4556"],"gpt_icon":0},{"id":"1118560812","title":"Beam Therapeutics公司：60毫克劑量被確定為最佳生物劑量，單劑量隊列展現優異安全性與療效","url":"https://stock-news.laohu8.com/highlight/detail?id=1118560812","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118560812?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 19:04","pubTimestamp":1774436652,"startTime":"0","endTime":"0","summary":"Beam Therapeutics公司宣布，基于单剂量队列中展现出的卓越安全性及疗效数据，60毫克剂量已被选定为最佳生物剂量。这一决定凸显了该剂量在治疗窗口中的优势地位，为后续临床开发奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1861559042.SGD","BK4556","BEAM","BK4535","BK4505","BK4585","BK4588","BK4611","LU1861558580.USD"],"gpt_icon":0},{"id":"1125593240","title":"Beam Therapeutics公布BEAM-302治療α-1抗胰蛋白酶缺乏症1/2期試驗最新積極數據 支持推進關鍵性開發階段","url":"https://stock-news.laohu8.com/highlight/detail?id=1125593240","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125593240?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 19:03","pubTimestamp":1774436620,"startTime":"0","endTime":"0","summary":"Beam Therapeutics近日公布了其在研疗法BEAM-302针对α-1抗胰蛋白酶缺乏症（AATD）的1/2期临床试验最新数据。这些积极结果有力支持该疗法向关键性临床开发阶段推进。试验数据显示，BEAM-302在安全性和有效性方面均表现出令人鼓舞的潜力，为后续研发奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4556","BK4585","BK4611","BK4535","BK4139","BK4505","LU1861559042.SGD","LU1861558580.USD","BEAM"],"gpt_icon":0},{"id":"1172694466","title":"Beam Therapeutics：經BEAM-302 60毫克治療後，校正型M-AAT佔總AAT的94%，同時突變型Z-AAT降低84%","url":"https://stock-news.laohu8.com/highlight/detail?id=1172694466","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172694466?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 19:03","pubTimestamp":1774436593,"startTime":"0","endTime":"0","summary":"在Beam Therapeutics公司BEAM-302 60毫克治疗方案下，研究数据显示校正型M-AAT占全部AAT的比例高达94%。与此同时，突变型Z-AAT水平出现显著下降，降幅达到84%。这一结果凸显了该疗法在精准编辑方面的潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","BK4588","BK4585","LU1861558580.USD","BK4535","BK4139","LU1861559042.SGD","BK4611","BEAM","BK4505"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}]}}